HIND

Vyome Holdings Inc

2.19

Jul 20 • 03:59PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: CMMB COCP CVKD HCWB INAB LEXX MTVA NCEL OSRH XCUR

Index	-
Market Cap	15.37M
Enterprise Value	7.89M
Income	-13.25M
Sales	1.34M
Book/sh	0.96
Cash/sh	1.25
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	18
IPO	Oct 06, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	11.47
P/B	2.28
P/C	1.75
P/FCF	-
EV/EBITDA	-
EV/Sales	5.89
Quick Ratio	4.27
Current Ratio	4.27
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-12.41
EPS next Y	-0.92
EPS next Q	-0.19
EPS this Y	85.33%
EPS next Y	-29.79%
EPS next 5Y	43.86%
EPS past 3/5Y	98.04% 93.71%
Sales past 3/5Y	-69.47% -50.98%
EPS Y/Y TTM	98.53%
Sales Y/Y TTM	-81.26%
EPS Q/Q	-100.19%
Sales Q/Q	-97.16%
Earnings	May 28 BMO
EPS/Sales Surpr.	0.00% -

Insider Own	52.82%
Insider Trans	0.00%
Inst Own	1.48%
Inst Trans	-0.76%
ROA	-159.01%
ROE	-332.39%
ROIC	-196.50%
Gross Margin	48.16%
Oper. Margin	-401.91%
Profit Margin	-985.46%
SMA20	0.11%
SMA50	1.00%
SMA200	-32.60%
Trades

Shs Outstand	7.02M
Shs Float	3.31M
Short Float	1.06%
Short Ratio	1.34
Short Interest	0.04M
52W High	18.60 -88.23%
52W Low	1.75 25.14%
Volatility	3.55% 4.68%
ATR (14)	0.11
RSI (14)	49.61
Beta	1.48
Rel Volume	0.00
Avg Volume	26.28K
Volume	0

Perf Week	-2.23%
Perf Month	0.46%
Perf Quarter	-0.90%
Perf Half Y	-29.13%
Perf YTD	-36.34%
Perf Year	-82.78%
Perf 3Y	-99.97%
Perf 5Y	-100.00%
Perf 10Y	-
Recom	1.00
Target Price	11.50
Prev Close	2.19
Price	2.19
Change	0.00%

Jul-01-26 08:00AM	Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio (Business Wire)
May-28-26 08:00AM	Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet (Business Wire)
May-12-26 08:00AM	Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity (Business Wire)
Apr-22-26 08:00AM	Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026 (Business Wire)
Apr-06-26 08:00AM	Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 (Business Wire)
07:00PM	Loading…
Mar-30-26 07:00PM	Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) +5.39%
Mar-26-26 08:00AM	Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase (Business Wire)
Feb-24-26 08:00AM	Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company (Business Wire) +8.28%
Feb-18-26 09:00AM	Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity (Business Wire) +6.84%
Feb-11-26 07:00AM	Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months (Business Wire)
Feb-02-26 07:00AM	Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results (Business Wire) +14.58%
Jan-27-26 08:00AM	Independent Analyst Values Vyomes VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study (Business Wire)
Dec-22-25 08:00AM	Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company (Business Wire) +5.43%
Dec-08-25 08:00AM	Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval (Business Wire) +14.37%
Nov-25-25 07:00AM	Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program (Business Wire)
07:00AM	Loading…
Nov-18-25 07:00AM	Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing (Business Wire)
Nov-04-25 09:04AM	Vyome Holdings Announces Results of Annual Shareholder Meeting (Business Wire)
Sep-29-25 07:00AM	Vyome Holdings Acquires MIT AI Spinout Oculo Health (Business Wire)
Sep-17-25 07:00AM	Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity (Business Wire)
Sep-09-25 08:30AM	Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies (Business Wire)
Sep-04-25 08:30AM	Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity (Business Wire) -9.06%
Aug-21-25 07:00AM	Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio (Business Wire) +21.91%
Aug-18-25 08:30AM	Vyome Announces Strategic Review of Livechain (OTCID: LICH) (Business Wire) -37.64%
Aug-15-25 02:57PM	Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market (Investing.com) -10.71%
08:00AM	Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell (Business Wire)
Aug-14-25 07:18PM	Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow (Business Wire) +22.50%

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. It focuses on therapeutic solutions that target formulations for site-targeted applications. The company was founded on January 2, 2008 and is headquartered in Cambridge, MA.

Co-FounderMr. Venkateswarlu Nelabhotla M.B.A.

Ph.D.Dr. Shiladitya Sengupta M.Sc.

Chief Financial OfficerMr. Robert Dickey IV

Chief Technology OfficerDr. Richard Fahrner Ph.D.

Investor Relations OfficerMr. Jules Abraham

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HIND

Vyome Holdings Inc

Upgrade your Finviz experience